Duloxetine Capsule, Delayed Release
Product Images NDC 68071-3979

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68071-3979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3979 6)

Label for Duloxetine 20 mg delayed-release capsules by NuCare Pharmaceuticals, Inc. The label states each capsule contains 22.4 mg of enteric-coated pellets equivalent to 20 mg Duloxetine Hydrochloride. The package contains 60 capsules. Includes NDC 68071-3979-6 and storage instructions to keep at controlled temperature 68-77°F. The label also shows manufacturing and expiration details and warns to keep out of reach of children.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier survival curve chart showing the proportion of patients with relapse over time in days from randomization. The chart compares two treatments: Duloxetine, represented by a solid line, and placebo, represented by a dashed line, depicting relapse rates up to around 200 days.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares placebo patients and patients receiving Duloxetine 60/120 mg once daily, with Duloxetine showing higher patient improvement across increasing pain improvement percentages.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A line graph showing the proportion of patients with relapse over time from randomization to relapse in days, comparing Duloxetine treatment to placebo. The x-axis represents time in days up to about 300, and the y-axis represents the proportion of patients with relapse from 0 to 1. Two lines are shown: a dashed line for placebo and a solid line for Duloxetine, with the Duloxetine group showing a lower proportion of relapse over time.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares the effects of Duloxetine at doses of 60 mg twice daily (BID), 60 mg once daily (QD), 20 mg QD, and placebo, illustrating patient response across various levels of pain improvement.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups, illustrating trends of patient improvement in pain levels with different treatments.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph illustrating the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The graph shows three curves comparing the efficacy of the two Duloxetine dosages with placebo over a range of pain improvement percentages.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing percent improvement in pain from baseline on the x-axis and percentage of patients improved on the y-axis. It compares four groups: Duloxetine 120 mg once daily, Duloxetine 60 mg once daily, Duloxetine 20 mg once daily, and placebo, tracking patient improvement percentages across various pain improvement thresholds.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, showing two lines: Duloxetine 60 mg once daily and placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily and placebo. The horizontal axis represents percent improvement in pain, ranging from >0 to 100. The vertical axis shows the percentage of patients improved from 0 to 100%. The Duloxetine group consistently shows higher patient improvement percentages compared to placebo across the pain improvement range.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. The graph includes two lines: one with crosses for placebo and one with diamonds for Duloxetine 60 mg once daily, with Duloxetine showing generally higher percentages of patient improvement across various pain improvement thresholds.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, showing its molecular configuration including a naphthalene ring, thiophene ring, and amine hydrochloride group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.